
Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized ...
read more ↘
read more ↘
Videos
ASCO GU 2023 Conference Coverage
ASCO GU 2023 Cell-Free utDNA to Detect MRD Prior to Repeat-Transurethral Resection of Bladder Tumor in NMIBC
FEATURING
Kyle Rose
- 29 views
- February 22, 2023
Moffitt Cancer Center
Expert Commentary: Hemicolectomy vs. Appendectomy for Patients With Appendiceal Neuroendocrine Tumours 1-2 cm in Size
FEATURING
Jonathan Strosberg
- 56 views
- February 14, 2023
- 1
ASCO GI 2023 Conference Coverage
ASCO GI 2023 Key Studies
FEATURING
Richard Kim,
Rutika Mehta
- 1,232 views
- February 3, 2023
- 10
ASCO GI 2023 Conference Coverage
ASCO GI 2023 ctDNA Informs Clinical Practice in Patients With Recurrent/Metastatic Gastroesophageal Cancers
FEATURING
Rutika Mehta
- 243 views
- January 31, 2023
- 2
Moffitt Cancer Center
MRD in CLL/SLL: Is It Ready for Prime Time?
FEATURING
Jose Sandoval-Sus
- 217 views
- January 25, 2023
- 5
CancerGRACE
Neoadjuvant Therapy for Advanced Melanoma: Does It Give a Better Immune Response?
FEATURING
Vernon Sondak
- 236 views
- January 19, 2023
- 2
CancerGRACE
Pros and Cons of Neoadjuvant Therapy for Melanoma
FEATURING
Vernon Sondak
- 53 views
- January 19, 2023
CancerGRACE
Patient Selection for 1L Therapy in Stage 4 Melanoma
FEATURING
Vernon Sondak
- 79 views
- January 19, 2023
ASH 2022 Conference Coverage
ASH 2022 Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated With HMA + Venetoclax Compared to CPX-351
FEATURING
Akriti Jain
- 273 views
- January 11, 2023
- 1
Moffitt Cancer Center
Advancing Neoadjuvant Therapy of Melanoma: SWOG Trials S1512 & S1801
FEATURING
Vernon Sondak
- 69 views
- December 21, 2022
ASH 2022 Conference Coverage
ASH 2022 Efficacy & Safety of Ruxolitinib for Treatment of Symptomatic CMML: Results of a Multicenter Phase II Clinical Trial
FEATURING
Eric Padron
- 33 views
- December 19, 2022
- 1
ASH 2022 Conference Coverage
ASH 2022: Validation of 2022 WHO & ICC Classifications in MDS - An Analysis on Behalf of the icMDS
FEATURING
Somedeb Ball
- 68 views
- December 19, 2022
- 3
Moffitt Cancer Center
NMIBC Unresponsive to BCG: Phase 2, Single Arm Study of CG0070 Combined with Pembro
FEATURING
Roger Li
- 28 views
- November 25, 2022
Moffitt Cancer Center
Lecture Summary - 2L Therapies for Chronic and Persistent ITP
FEATURING
Vania Phuoc
- 8 views
- July 11, 2022
Moffitt Cancer Center
2L Therapies for Chronic and Persistent ITP
FEATURING
Vania Phuoc
- 87 views
- July 11, 2022
- 1
Moffitt Cancer Center
Symptom Assessments in Myelofibrosis and How to Measure Spleen
FEATURING
Andrew Kuykendall
- 50 views
- May 27, 2022
Moffitt Cancer Center
Genetic Risk Stratification for Prostate Cancer: Genomics, Ancestry, and Disparities
FEATURING
Tyler Seibert
- 49 views
- April 13, 2022
Moffitt Cancer Center
Use of Cemiplimab in Locally Advanced Basal Cell Carcinomas After Hedgehog Inhibitor Therapy
FEATURING
Zeynep Eroglu
- 99 views
- March 1, 2022
Moffitt Cancer Center
Patients With Brain Tumors: New Tools and Techniques for Improved Surgical Outcomes
FEATURING
Michael Vogelbaum
- 9 views
- September 21, 2021
Emerging Treatments in Oncology Weekly
Episode 3: Radiation Therapy in Merkel Cell Carcinoma in a Multidisciplinary Setting
FEATURING
Evan Wuthrick
- 20 views
- August 20, 2021
Emerging Treatments in Oncology Weekly
Episode 2: Surgical Treatment of Merkel Cell Carcinoma in a Multidisciplinary Setting
FEATURING
Rogerio Neves
- 190 views
- August 10, 2021
- 4
Moffitt Cancer Center
2021 ASCO Updates on Triplet Therapy for Patients With BRAF-Mutated Advanced Melanoma
FEATURING
Zeynep Eroglu
- 529 views
- July 5, 2021
- 1
Moffitt Cancer Center
2021 ASCO Updates on KTE-X19 CAR T-Cell for Adult R/R B-Cell ALL: ZUMA-3 Study Data
FEATURING
Bijal Shah
- 46 views
- June 29, 2021
Moffitt Cancer Center
Improved Tolerability of Neratinib in Patients With HER2+ EBC: The CONTROL Trial
FEATURING
Hatem Soliman
- 345 views
- June 16, 2021
- 1
Moffitt Cancer Center
World Lung IMpower133 Update on Maintenance Therapy in ES-SCLC: OS and PD-L1 Subgroup Data for Atezo Mono
FEATURING
Bruna Pellini
- 138 views
- May 20, 2021
Moffitt Cancer Center
2021 Update on Pancoast Tumors: Signs & Symptoms, Treatment Options, Surgical Treatment Approaches & Outcomes
FEATURING
Nam Tran
- 40 views
- April 13, 2021
- 1
Moffitt Cancer Center
Cardio-Oncology Program at Moffitt Cancer Center: What Is Cardio-Oncology Program & Its Benefits?
FEATURING
Guilherme Oliveira
- 5 views
- March 1, 2021
Moffitt Cancer Center
Monitoring, Prevention & Management of CVD in Cancer Patients: Which Patients Are at Increased Risk for Cardiac Dysfunction? Can Biomarkers and Strain Imaging Help With the Early Diagnosis? What Are the Management Recommendations?
FEATURING
Mohammed Alomar
- 79 views
- March 1, 2021
- 1
Moffitt Cancer Center
Hypotension in the Oncology Clinic Patients: Diagnosis, Management & Clinical Pearls
FEATURING
Mark Honor
- 3 views
- February 26, 2021
Moffitt Cancer Center
61 y/o Male on Oral Chemo With Poor Intake, Longstanding History of HCTZ, and DM, BP 88/59: How to Approach Treatment?
FEATURING
Mark Honor
- 3 views
- February 26, 2021
Moffitt Cancer Center
62 y/o Male With Tongue SCC, Hypothyroidism, OA, and Autonomic Neuropathy Causing Hypotension: How to Diagnose & Treat?
FEATURING
Mark Honor
- 4 views
- February 26, 2021
Moffitt Cancer Center
AL Amyloidosis at Moffitt: How Does SCT Affect OS? Is Bortezomib/Ixazomib the Best Choice for Recurrent Disease vs. Mel/Dex? Is Doxycycline Beneficial After ASCT? Can We Achieve CHR With Dara+CyBorD in Newly Diagnosed Patients?
FEATURING
Brandon Blue
- 115 views
- February 2, 2021
- 1
Moffitt Cancer Center
Is Anti-CD38 Isatuximab-irfc Effective for R/R Multiple Myeloma?
FEATURING
Kenneth Shain
- 414 views
- January 8, 2021
- 1
Association of Community Cancer Centers (ACCC)
New Treatment Paradigms in Advanced CSCC
FEATURING
Nikhil Khushalani
- 199 views
- December 29, 2020
- 1
Moffitt Cancer Center
Moffitt Cancer Center Update on Metastatic Pancreatic Cancer: Does Nal-IRI+5FU/LV After Previous Gem-Based Chemo Improve OS?
FEATURING
Dae Kim
- 181 views
- December 28, 2020
Moffitt Cancer Center
Moffitt Cancer Center Update on Advanced HCC: Is 1L Sorafenib Beneficial vs. Atezo + Bev? Can TKIs Be Used as 2L/3L Therapy?
FEATURING
Richard Kim
- 170 views
- December 28, 2020
- 1
Moffitt Cancer Center
Moffitt Cancer Center’s 2020 Update on MPNs: Overview, Epidemiology, Mutations, Prognostic Markers, Risk Factors
FEATURING
Andrew Kuykendall
- 257 views
- December 15, 2020
- 1
Moffitt Cancer Center
COVID-19: Are Family & Upcoming Large Holiday Gatherings Safe? Can Close Contact and Intense Physical Activity Contribute to Spread?
FEATURING
John Greene
- 3,492 views
- November 26, 2020
- 25
Moffitt Cancer Center
Melanoma Drug Therapy During COVID-19: When to Wait or Go Forward With the Adjuvant Treatment? Does IO Help Fight Coronavirus? Are Pts on Steroids at Higher Risk for the Virus? How Long After a Treatment a Patient Should Be Monitored?
FEATURING
Zeynep Eroglu,
Vernon Sondak
- 375 views
- November 16, 2020
- 1
Moffitt Cancer Center
Treatment Options in Ovarian Cancer: What Role Do Maintenance PARPi Play? How Does HIPEC OS Data Compare to IV/IP + Bev?
FEATURING
Robert Wenham
- 96 views
- November 13, 2020
Moffitt Cancer Center
2020 Updates on Genetic Testing for GYN Malignancies: Germline vs. Somatic Mutations - What Is the Risk for Ovarian Cancer?
FEATURING
Jeannie Chern
- 194 views
- November 13, 2020
Moffitt Cancer Center
Surgical Options in Endometrial Cancer: How We Have Advanced to Minimally Invasive Surgery as the Standard Approach
FEATURING
Mitchel Hoffman
- 15 views
- November 13, 2020